Abstract：Objective To systematically evaluate the efficacy and safety of serotonin-selective reuptake inhibitor (SSRIS) in the treatment of Alzheimer’s disease patients with depression. Methods The databases of PubMed, Embase, CNKI, Wanfang Data, VIP were electronically searched for relevant studies from inceptions to May 2021. Two reviewers independently screened the literature, extracted data and assessed the methodolgical quality. And meta analysis was performed by using RevMan 5.3. Results A total of seven studies with 438 patients were included. The results of meta analysis showed that there were no significant differences in the effective rate (OR = 2.33, 95%CI: 0.69-7.91, P = 0.17), the score of Cornell scale for depression in dementia (MD = -2.52, 95%CI: -6.19-1.15, P = 0.18), the score of simple mental state examination scale (MD = -0.30, 95%CI: -0.82-1.41, P = 0.60) and the incidence of adverse reactions (OR = 1.21, 95%CI: 0.65-2.26, P = 0.55) between two groups. Conclusion The efficacy and safety of SSRIS in the treatment of patients with AD concomitant depression are comparable to that of placebo.
宋帆 唐新龙 程凤先 童庆好. 5-羟色胺选择性重摄取抑制剂治疗阿尔茨海默病伴发抑郁症患者有效性和安全性的meta分析[J]. 中国医药导报, 2022, 19(20): 75-78.
SONG Fan TANG Xinlong CHENG Fengxian TONG Qinghao. Meta analysis on the efficacy and safety of selective serotonin reuptake inhibitor in the treatment of Alzheimer’s disease with depression. 中国医药导报, 2022, 19(20): 75-78.
[1] Galts CPC，Bettio LEB，Jewett DC，et al. Depression in neuro-degenerative diseases：common mechanisms and current tre-atment options [J]. Neurosci Biobehav Rev，2019，102：56-84.
[2] Guo Z，Liu X，Hou H，et al. Abnormal degree centrality in Alzheimer’s disease patients with depression：a resting-state functional magnetic resonance imaging study [J]. Exp Gerontol，2016，79：61-66.
[3] Yang H，Hong W，Chen L，et al. Analysis of risk factors for depression in Alzheimer’s disease patients [J]. Int J Neurosci，2020，130（11）：1136-1141.
[4] Ryu SH，Jung HY，Lee KJ，et al. Incidence and course of depression in patients with Alzheimer’s disease [J]. Psychiatry Investig，2017，14（3）：271-280.
[5] Elsworthy RJ，Aldred S. Depression in Alzheimer’s disease：an alternative role for selective serotonin reuptake inhibitors? [J]. J Alzheimers Dis，2019，69（3）：651-661.
[6] Banerjee S，Hellier J，Dewey M，et al. Sertraline or mirtazapine for depression in dementia （HTA-SADD）：a randomised，multicentre，double-blind，placebo-controlled trial [J]. Lancet，2011，378（9789）：403-411.
[7] Lyketsos CG，DelCampo L，Steinberg M，et al. Treating depression in Alzheimer disease：efficacy and safety of sertraline therapy，and the benefits of depression reduction：the DIADS [J]. Arch Gen Psychiatry，2003，60（7）：737-746.
[8] Magai C，Kennedy G，Cohen CI，et al. A controlled clinical trial of sertraline in the treatment of depression in nursing home patients with late-stage Alzheimer’s disease [J]. Am J Geriatr Psychiatry，2000，8（1）：66-74.
[9] Rosenberg PB，Drye LT，Martin BK，et al. Sertraline for the treatment of depression in Alzheimer disease [J]. Am J Geriatr Psychiatry，2010，18（2）：136-145.
[10] 陈梅芳.舍曲林对阿尔茨海默病伴发抑郁症状的疗效及认知功能的影响[J].海峡药学，2014，26（7）：90-92.
[11] An H，Choi B，Park KW，et al. The effect of escitalopram on mood and cognition in depressive Alzheimer’s disease subjects [J]. J Alzheimers Dis，2017，55（2）：727-735.
[12] Petracca GM，Chemerinski E，Starkstein SE. A double-blind，placebo-controlled study of fluoxetine in depressed patients with Alzheimer’s disease [J]. Int Psychogeriatr，2001，13（2）：233-240.
[13] Nyth AL，Gottfries CG. The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. A Nordic multicentre study [J]. Br J Psychiatry，1990，157：894-901.
[14] Hendricksen M，Thomas AJ，Ferrier IN，et al. Neuropathological study of the dorsal raphe nuclei in late-life depression and Alzheimer’s disease with and without depression [J]. Am J Psychiatry，2004，161（6）：1096-1102.
[15] Khundakar AA，Thomas AJ. Neuropathology of depression in Alzheime’s disease：current knowledge and the potential for new treatments [J]. J Alzheimers Dis，2015， 44（1）：27-41.
[16] Wilkins JM，Forester BP. Update on SSRI treatment for neuropsychiatric symptoms of dementia [J]. Curr Psychiatry Rep，2016，18（2）：14.
[17] 田金洲，解恒革，王鲁宁，等.中国阿尔茨海默病痴呆诊疗指南（2020年版）[J].中华老年医学杂志，2021，40（3）：269-283.
[18] Pelton GH，Harper OL，Tabert MH，et al. Randomized double-blind placebo-controlled donepezil augmentation in antidepressant-treated elderly patients with depression and cognitive impairment：a pilot study [J]. Int J Geriatr Psychiatry，2008，23（7）：670-676.
[19] 方圆，李晓晖，吕雪梅，等.西酞普兰联合多奈哌齐对阿尔兹海默病抑郁症状及认知功能的疗效观察[J].中国现代医药杂志，2018，20（3）：33-35.
[20] Orgeta V，Qazi A，Spector A，et al. Psychological treatments for depression and anxiety in dementia and mild cognitive impairment：systematic review and meta-analysis [J]. Br J Psychiatry，2015，207（4）：293-298.
[21] Watt J，Goodarzi Z，Tricco AC，et al. Comparative safety and efficacy of pharmacological and non-pharmacological interventions for the behavioral and psychological symptoms of dementia：protocol for a systematic review and network meta-analysis [J]. Syst Rev，2017，6（1）：182.
[22] Watt JA，Goodarzi Z，Veroniki AA，et al. Comparative efficacy of interventions for reducing symptoms of depression in people with dementia：systematic review and network meta-analysis [J]. BMJ，2021，372：n532.
[23] Whitehead L. Psychological treatments for depression and anxiety in dementia and mild cognitive impairment [J]. Issues Ment Health Nurs，2016，37（10）：773-774.
[24] Gómez Gallego M，Gómez García J. Music therapy and Alzheimer’s disease：cognitive，psychological，and behavioural effects [J]. Neurologia，2017，32（5）：300-308.
[25] Seibert M，Mühlbauer V，Holbrook J，et al. Efficacy and safety of pharmacotherapy for Alzheimer’s disease and for behavioural and psychological symptoms of dementia in older patients with moderate and severe functional impairments：a systematic review of controlled trials [J]. Alzheimers Res Ther，2021，13（1）：131.
京公网安备 11010502046598号